In the pharmaceutical industry, the use of generative AI is not limited to R&D. Using different technologies (GPT, Claude, Llama), Sanofi has designed a model for its annual product quality reviews, “for which there is no global standard yet”says Maïté Durrenbach, the group’s quality manager.
These 100- to 150-page regulatory reports are compiled for each factory and each drug. Sanofi files 3,500 of them per year with health authorities. They compile all the production data, including problems, and then draw conclusions.
«The idea was to generate these reports automatically with generative AI and come up with conclusions. Our teams check the work, but the quality and relevance of what we get is mind-blowing.”says Maïté Durrenbach. Who specifies that today, “iIt takes 120 hours to put together such a report. With our GenAIr tool (for “gen AI reporting”), it only takes a few minutes. We go from 120 to 15 hours, counting the verification time and the few small sections still kept in manual».
Sanofi launched GenAIR in early April and plans to roll it out before the end of 2024 in all its factories around the world.The primary objective is cost and time savings.underlines Maïté Durrenbach. Generative AI does not replace humans, but the combination of the two allows us to reallocate time and resources to our value-added activities.»
You are reading an article from L’Usine Nouvelle 3731 – June 2024
Read the summary
Source: www.usinenouvelle.com
